{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:31:09Z","timestamp":1786649469973,"version":"build-2736575974"},"reference-count":128,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Intestinal failure\u2013associated liver disease (IFALD) remains one of the most common and serious complications of parenteral nutrition (PN), causing a wide spectrum of hepatic manifestations from steatosis and mild cholestasis to portal hypertension and end-stage liver failure. The prevalence of IFALD depends on the diagnostic criteria and ranges from 4.3% to 65%. Moreover, many factors are shown to contribute to its development, including nutrient deficiencies, toxicity of PN, infections, and alterations of bile acid metabolism and gut microbiota. Prevention and management of IFALD aim at ameliorating or eliminating the risk factors associated with IFALD. The use of PN formulations with a lower ratio omega-6-to-omega-3 polyunsaturated fatty acids, cycle PN, optimization of enteral stimulation and prevention and early treatment of infections constitute the main therapeutic targets. However, failure of improvement and severe IFALD with end-stage liver failure should be considered as the indications of intestinal transplantation. The aim of this review is to provide an update of the epidemiology, pathophysiology, and diagnosis of IFALD in the adult population as well as to present a clinical approach of the therapeutic strategies of IFALD and present novel therapeutic targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_551_20","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T05:54:04Z","timestamp":1612850044000},"page":"3-12","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["New insights into intestinal failure\u2013associated liver disease in adults"],"prefix":"10.4103","volume":"27","author":[{"given":"Fotios S.","family":"Fousekis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis V.","family":"Mitselos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios K.","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240829","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clnu.2014.08.017","article-title":"ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults","volume":"34","author":"Pironi","year":"2015","journal-title":"Clin Nutr"},{"key":"R2-2-20240829","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clnu.2016.01.020","article-title":"ESPEN guidelines on chronic intestinal failure in adults","volume":"35","author":"Pironi","year":"2016","journal-title":"Clin Nutr"},{"key":"R3-2-20240829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gtc.2017.10.001","article-title":"Parenteral nutrition: Indications, access, and complications","volume":"47","author":"Lappas","year":"2018","journal-title":"Gastroenterol Clin North Am"},{"key":"R4-2-20240829","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clnu.2009.04.024","article-title":"ESPEN guidelines on Parenteral nutrition: Intensive care","volume":"28","author":"Singer","year":"2009","journal-title":"Clin Nutr"},{"key":"R5-2-20240829","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11892-012-0335-y","article-title":"Management of hyperglycemia during enteral and parenteral nutrition therapy","volume":"13","author":"Gosmanov","year":"2013","journal-title":"Curr Diab Rep"},{"key":"R6-2-20240829","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1051-0443(07)61865-X","article-title":"Central venous catheters in home infusion care: Outcomes analysis in 50,470 patients","volume":"13","author":"Moureau","year":"2002","journal-title":"J Vasc Interv Radiol"},{"key":"R7-2-20240829","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clnu.2012.08.004","article-title":"Epidemiology of catheter-related infections in adult patients receiving home parenteral nutrition: A systematic review","volume":"32","author":"Dreesen","year":"2013","journal-title":"Clin Nutr"},{"key":"R8-2-20240829","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1054\/clnu.2002.0548","article-title":"Prevalence of bone disease in patients on home parenteral nutrition","volume":"21","author":"Pironi","year":"2002","journal-title":"Clin Nutr"},{"key":"R9-2-20240829","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/0016-5085(83)90204-4","article-title":"Does total parenteral nutrition induce gallbladder sludge formation and lithiasis?","volume":"84","author":"Messing","year":"1983","journal-title":"Gastroenterology"},{"key":"R10-2-20240829","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0115426506021003279","article-title":"Parenteral nutrition-associated liver disease in adult and pediatric patients","volume":"21","author":"Kumpf","year":"2006","journal-title":"Nutr Clin Pract"},{"key":"R11-2-20240829","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MPG.0000000000000586","article-title":"Intestinal failure-associated liver disease: A position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation","volume":"60","author":"Lacaille","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R12-2-20240829","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.clnu.2018.07.006","article-title":"Clinical approach to the management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN","volume":"37","author":"Lal","year":"2018","journal-title":"Clin Nutr"},{"key":"R13-2-20240829","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1053\/j.gastro.2005.10.066","article-title":"Intestinal failure-associated liver disease: What do we know today?","volume":"130","author":"Kelly","year":"2006","journal-title":"Gastroenterology"},{"key":"R14-2-20240829","first-page":"573","article-title":"Serum hepatic enzyme and bilirubin elevations during parenteral nutrition","volume":"145","author":"Grant","year":"1977","journal-title":"Surg Gynecol Obstet"},{"key":"R15-2-20240829","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cld.2017.06.008","article-title":"Liver disease in patients on total parenteral nutrition","volume":"21","author":"Mitra","year":"2017","journal-title":"Clin Liver Dis"},{"key":"R16-2-20240829","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1089-3261(03)00130-2","article-title":"Postoperative jaundice","volume":"8","author":"Faust","year":"2004","journal-title":"Clin Liver Dis"},{"key":"R17-2-20240829","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-132-7-200004040-00003","article-title":"Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure","volume":"132","author":"Cavicchi","year":"2000","journal-title":"Ann Intern Med"},{"key":"R18-2-20240829","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2036.2008.03615.x","article-title":"Chronic biochemical cholestasis in patients receiving home parenteral nutrition: Prevalence and predisposing factors","volume":"27","author":"Lloyd","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-2-20240829","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/msy.1999.98925","article-title":"Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition","volume":"126","author":"Chan","year":"1999","journal-title":"Surgery"},{"key":"R20-2-20240829","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.clnu.2018.04.019","article-title":"Assessment of intestinal failure associated liver disease according to different diagnostic criteria","volume":"38","author":"Sasdelli","year":"2019","journal-title":"Clin Nutr"},{"key":"R21-2-20240829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1054\/clnu.2002.0554","article-title":"Prevalence, outcome and associated factors of deranged liver function tests in patients on home parenteral nutrition","volume":"21","author":"Luman","year":"2002","journal-title":"Clin Nutr"},{"key":"R22-2-20240829","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/liv.13545","article-title":"Ultra-short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition","volume":"38","author":"Cazals-Hatem","year":"2018","journal-title":"Liver Int"},{"key":"R23-2-20240829","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0148607106030003202","article-title":"Liver failure is uncommon in adults receiving long-term parenteral nutrition","volume":"30","author":"Salvino","year":"2017","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R24-2-20240829","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MOG.0000000000000503","article-title":"Intestinal failure-associated liver disease: Causes, manifestations and therapies","volume":"35","author":"Rochling","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"R25-2-20240829","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/fg.2009.000521","article-title":"Abnormal liver function tests in the parenteral nutrition fed patient","volume":"1","author":"Gabe","year":"2010","journal-title":"Frontline Gastroenterol"},{"key":"R26-2-20240829","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ajcn\/43.1.85","article-title":"Plasma carnitine levels in patients receiving home parenteral nutrition","volume":"43","author":"Bowyer","year":"1986","journal-title":"Am J Clin Nutr"},{"key":"R27-2-20240829","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1053\/j.gastro.2009.08.016","article-title":"Carnitine in parenteral nutrition","volume":"137","author":"Borum","year":"2009","journal-title":"Gastroenterology"},{"key":"R28-2-20240829","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/cells1041261","article-title":"Signals and cells involved in regulating liver regeneration","volume":"1","author":"Kang","year":"2012","journal-title":"Cells"},{"key":"R29-2-20240829","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/hep4.1207","article-title":"L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis","volume":"2","author":"Ohara","year":"2018","journal-title":"Hepatol Commun"},{"key":"R30-2-20240829","doi-asserted-by":"crossref","first-page":"e100627","DOI":"10.1371\/journal.pone.0100627","article-title":"L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway","volume":"9","author":"Ishikawa","year":"2014","journal-title":"PloS One"},{"key":"R31-2-20240829","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/dc14-2852","article-title":"Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in type 2 diabetes (CORONA): A randomized controlled trial","volume":"38","author":"Bae","year":"2015","journal-title":"Diabetes Care"},{"key":"R32-2-20240829","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0016-5085(88)90433-7","article-title":"l-Carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentrations","volume":"94","author":"Bowyer","year":"1988","journal-title":"Gastroenterology"},{"key":"R33-2-20240829","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM198501173120302","article-title":"Nutritional requirement for taurine in patients receiving long-term parenteral nutrition","volume":"312","author":"Geggel","year":"1985","journal-title":"N Engl J Med"},{"key":"R34-2-20240829","first-page":"262","article-title":"Taurine: A conditionally essential amino acid in humans? An overview in health and disease","volume":"17","author":"Lourenco","year":"2002","journal-title":"Nutr Hosp"},{"key":"R35-2-20240829","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1600-0676.1991.tb00510.x","article-title":"The effect of taurine on the cholestatic potential of sulfated lithocholate and its conjugates","volume":"11","author":"Belli","year":"1991","journal-title":"Liver"},{"key":"R36-2-20240829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0148607105029005337","article-title":"Parenteral nutrition-associated cholestasis in neonates: Multivariate analysis of the potential protective effect of taurine","volume":"29","author":"Spencer","year":"2005","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R37-2-20240829","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/0884533614533610","article-title":"Phase IV prospective clinical study to evaluate the effect of taurine on liver function in postsurgical adult patients requiring parenteral nutrition","volume":"29","author":"Arrieta","year":"2014","journal-title":"Nutr Clin Pract"},{"key":"R38-2-20240829","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MOL.0b013e3282fee935","article-title":"Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis","volume":"19","author":"Vance","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"R39-2-20240829","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0261-5614(93)90143-R","article-title":"Low plasma free choline is prevalent in patients receiving long term parenteral nutrition and is associated with hepatic aminotransferase abnormalities","volume":"12","author":"Buchman","year":"1993","journal-title":"Clin Nutr"},{"key":"R40-2-20240829","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MOG.0b013e32834e7b4b","article-title":"Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression","volume":"28","author":"Corbin","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"R41-2-20240829","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0148607101025005260","article-title":"Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: Proof of a human choline requirement: A placebo-controlled trial","volume":"25","author":"Buchman","year":"2001","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R42-2-20240829","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/0016-5085(92)90777-V","article-title":"Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients","volume":"102","author":"Buchman","year":"1992","journal-title":"Gastroenterology"},{"key":"R43-2-20240829","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1872-034X.2012.00976.x","article-title":"Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study","volume":"42","author":"Imajo","year":"2012","journal-title":"Hepatol Res"},{"key":"R44-2-20240829","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0148607110386964","article-title":"Serum vitamins in adult patients with short bowel syndrome receiving intermittent parenteral nutrition","volume":"35","author":"Braga","year":"2011","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R45-2-20240829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.nut.2018.11.012","article-title":"Familial vitamin E deficiency: Multiorgan complications support the adverse role of oxidative stress","volume":"63-64","author":"Trotta","year":"2019","journal-title":"Nutrition"},{"key":"R46-2-20240829","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.3390\/nu6125473","article-title":"Does vitamin C deficiency promote fatty liver disease development?","volume":"6","author":"Ipsen","year":"2014","journal-title":"Nutrients"},{"key":"R47-2-20240829","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"31","author":"Sato","year":"2015","journal-title":"Nutrition"},{"key":"R48-2-20240829","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0148607114567900","article-title":"Vitamin E in new-generation lipid emulsions protects against parenteral nutrition\u2013associated liver disease in parenteral nutrition\u2013fed preterm pigs","volume":"40","author":"Ng","year":"2015","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R49-2-20240829","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/0148607116667060","article-title":"Management of parenteral nutrition in hospitalized adult patients [Formula: See text]","volume":"41","author":"Mundi","year":"2017","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R50-2-20240829","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0022-4804(88)90095-9","article-title":"Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats","volume":"44","author":"Li","year":"1988","journal-title":"J Surg Res"},{"key":"R51-2-20240829","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cphy.c130024","article-title":"Energy metabolism in the liver","volume":"4","author":"Rui","year":"2014","journal-title":"Compr Physiol"},{"key":"R52-2-20240829","first-page":"1347","article-title":"Early use of cyclic TPN prevents further deterioration of liver functions for the TPN patients with impaired liver function","volume":"47","author":"Hwang","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"R53-2-20240829","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0032-1329903","article-title":"Prevention and treatment of intestinal failure-associated liver disease in children","volume":"32","author":"Raphael","year":"2013","journal-title":"Semin Liver Dis"},{"key":"R54-2-20240829","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3945\/an.113.004770","article-title":"Treatment of parenteral nutrition-associated liver disease: The role of lipid emulsions","volume":"4","author":"Nandivada","year":"2013","journal-title":"Adv Nutr"},{"key":"R55-2-20240829","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1177\/0148607115595978","article-title":"Phytosterols, lipid administration, and liver disease during parenteral nutrition","volume":"39","author":"Zaloga","year":"2015","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R56-2-20240829","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0899-9007(97)00233-5","article-title":"The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition","volume":"14","author":"Clayton","year":"1998","journal-title":"Nutrition"},{"key":"R57-2-20240829","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.nut.2008.06.017","article-title":"Phytosterolemia in parenteral nutrition patients: Implications for liver disease development","volume":"24","author":"Llop","year":"2008","journal-title":"Nutrition"},{"key":"R58-2-20240829","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clnu.2005.01.001","article-title":"High serum phytosterol levels in short bowel patients on parenteral nutrition support","volume":"24","author":"Elleg\u00e5rd","year":"2005","journal-title":"Clin Nutr"},{"key":"R59-2-20240829","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/ejcn.2012.219","article-title":"Aluminium in parenteral nutrition: A systematic review","volume":"67","author":"Hernandez-Sanchez","year":"2013","journal-title":"Eur J Clin Nutr"},{"key":"R60-2-20240829","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nut.2009.10.015","article-title":"Aluminum contamination in products used in parenteral nutrition: Has anything changed?","volume":"26","author":"Gura","year":"2010","journal-title":"Nutrition"},{"key":"R61-2-20240829","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jhazmat.2011.05.100","article-title":"Prophylactic and therapeutic effects of taurine against aluminum-induced acute hepatotoxicity in mice","volume":"192","author":"El-Sayed","year":"2011","journal-title":"J Hazard Mater"},{"key":"R62-2-20240829","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/0148607112454543","article-title":"Effects of manganese from a commercial multi-trace element supplement in a population sample of Canadian patients on long-term parenteral nutrition","volume":"37","author":"Abdalian","year":"2013","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R63-2-20240829","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.gastro.2009.08.011","article-title":"Manganese in parenteral nutrition: Who, when, and why should we supplement?","volume":"137","author":"Hardy","year":"2009","journal-title":"Gastroenterology"},{"key":"R64-2-20240829","first-page":"577","article-title":"Physiologic and morphologic natural history of a model of intrahepatic cholestasis (manganese-bilirubin overload)","volume":"66","author":"Witzleben","year":"1972","journal-title":"Am J Pathol"},{"key":"R65-2-20240829","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/0006-2952(85)90435-6","article-title":"Hepatic subcellular distribution of manganese in manganese and manganese-bilirubin induced cholestasis","volume":"34","author":"Ayotte","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"R66-2-20240829","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3390\/nu9090987","article-title":"Parenteral nutrition-associated liver disease: The role of the gut microbiota","volume":"9","author":"Cahova","year":"2017","journal-title":"Nutrients"},{"key":"R67-2-20240829","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/microorganisms4010016","article-title":"Extensive intestinal resection triggers behavioral adaptation, intestinal remodeling and microbiota transition in short bowel syndrome","volume":"4","author":"Mayeur","year":"2016","journal-title":"Microorganisms"},{"key":"R68-2-20240829","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.biochi.2010.02.015","article-title":"Drastic changes in fecal and mucosa-associated microbiota in adult patients with short bowel syndrome","volume":"92","author":"Joly","year":"2010","journal-title":"Biochimie"},{"key":"R69-2-20240829","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/jgh.13806","article-title":"Fecal microbiota signatures of adult patients with different types of short bowel syndrome","volume":"32","author":"Huang","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"R70-2-20240829","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jhep.2014.06.025","article-title":"Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease","volume":"61","author":"Pereira-Fantini","year":"2014","journal-title":"J Hepatol"},{"key":"R71-2-20240829","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0022-3476(97)80058-3","article-title":"Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome","volume":"131","author":"Kaufman","year":"1997","journal-title":"J Pediatr"},{"key":"R72-2-20240829","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jgh3.12174","article-title":"Small intestinal bacterial overgrowth in children with intestinal failure on home parenteral nutrition","volume":"3","author":"McGrath","year":"2019","journal-title":"JGH Open"},{"key":"R73-2-20240829","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.3390\/nu6125583","article-title":"The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease","volume":"6","author":"Ferolla","year":"2014","journal-title":"Nutrients"},{"key":"R74-2-20240829","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MEG.0000000000001541","article-title":"Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"32","author":"Wijarnpreecha","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R75-2-20240829","doi-asserted-by":"crossref","first-page":"159","DOI":"10.15403\/jgld.2014.1121.252.iwg","article-title":"Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease","volume":"25","author":"Fialho","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"R76-2-20240829","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.surg.2012.04.001","article-title":"Parenteral nutrition suppresses the bactericidal response of the small intestine","volume":"153","author":"Omata","year":"2013","journal-title":"Surgery"},{"key":"R77-2-20240829","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e318277ea9e","article-title":"IL-25 Improves IgA levels during parenteral nutrition through the JAK-STAT pathway","volume":"258","author":"Heneghan","year":"2013","journal-title":"Ann Surg"},{"key":"R78-2-20240829","first-page":"185","article-title":"Total parenteral nutrition promotes bacterial translocation from the gut","volume":"104","author":"Alverdy","year":"1988","journal-title":"Surgery"},{"key":"R79-2-20240829","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fcimb.2013.00105","article-title":"Intestinal epithelial cell apoptosis and loss of barrier function in the setting of altered microbiota with enteral nutrient deprivation","volume":"3","author":"Demehri","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"key":"R80-2-20240829","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2015.03.012","article-title":"Intestinal failure to produce FGF19: A culprit in intestinal failure-associated liver disease?","volume":"62","author":"van Erpecum","year":"2015","journal-title":"J Hepatol"},{"key":"R81-2-20240829","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2006.01731.x","article-title":"Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man","volume":"260","author":"Lundasen","year":"2006","journal-title":"J Intern Med"},{"key":"R82-2-20240829","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/hep.25929","article-title":"Emerging role of fibroblast growth factors 15\/19 and 21 as metabolic integrators in the liver","volume":"56","author":"Cicione","year":"2012","journal-title":"Hepatology"},{"key":"R83-2-20240829","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jhep.2015.01.004","article-title":"Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure","volume":"62","author":"Mutanen","year":"2015","journal-title":"J Hepatol"},{"key":"R84-2-20240829","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S1499-3872(12)60229-X","article-title":"Pathogenesis and treatment of parenteral nutrition-associated liver disease","volume":"11","author":"Xu","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R85-2-20240829","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0148607111413598","article-title":"The role of parenteral lipids in the development of advanced intestinal failure-associated liver disease in infants: A multiple-variable analysis","volume":"35","author":"Diamond","year":"2011","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R86-2-20240829","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5301\/jva.5000133","article-title":"Catheter-related complications in long-term home parenteral nutrition patients with chronic intestinal failure","volume":"13","author":"Guglielmi","year":"2012","journal-title":"J Vasc Access"},{"key":"R87-2-20240829","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpedsurg.2008.10.033","article-title":"The association of cyclic parenteral nutrition and decreased incidence of cholestatic liver disease in patients with gastroschisis","volume":"44","author":"Jensen","year":"2009","journal-title":"J Pediatr Surg"},{"key":"R88-2-20240829","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0884533610368701","article-title":"Metabolic effects of cyclic parenteral nutrition infusion in adults and children","volume":"25","author":"Stout","year":"2010","journal-title":"Nutr Clin Pract"},{"key":"R89-2-20240829","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.clnu.2012.06.011","article-title":"Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid)--a double-blind, randomised, multicentre study in adults","volume":"32","author":"Klek","year":"2013","journal-title":"Clin Nutr"},{"key":"R90-2-20240829","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clnu.2016.01.020","article-title":"ESPEN guidelines on chronic intestinal failure in adults","volume":"35","author":"Pironi","year":"2016","journal-title":"Clin Nutr"},{"key":"R92-2-20240829","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/147323000803600326","article-title":"Comparison of soybean oil- and olive oil-based lipid emulsions on hepatobiliary function and serum triacylglycerols level during realimentation","volume":"36","author":"Palova","year":"2008","journal-title":"J Int Med Res"},{"key":"R93-2-20240829","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12937-015-0100-6","article-title":"Safety and efficacy of an olive oil-based triple-chamber bag for parenteral nutrition: A prospective, randomized, multi-center clinical trial in China","volume":"14","author":"Jia","year":"2015","journal-title":"Nutr J"},{"key":"R94-2-20240829","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0148607106030004351","article-title":"New parenteral lipid emulsions for clinical use","volume":"30","author":"Waitzberg","year":"2006","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R95-2-20240829","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jnutbio.2017.09.017","article-title":"Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology","volume":"52","author":"Khadge","year":"2018","journal-title":"J Nutr Biochem"},{"key":"R96-2-20240829","doi-asserted-by":"crossref","first-page":"e12271","DOI":"10.1097\/MD.0000000000012271","article-title":"Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"97","author":"Yan","year":"2018","journal-title":"Medicine"},{"key":"R97-2-20240829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clnu.2011.10.001","article-title":"Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults","volume":"31","author":"Xu","year":"2012","journal-title":"Clin Nutr"},{"key":"R98-2-20240829","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nut.2012.07.009","article-title":"Successful treatment of parenteral nutrition-associated liver disease in an adult by use of a fish oil-based lipid source","volume":"29","author":"Venecourt-Jackson","year":"2013","journal-title":"Nutrition"},{"key":"R99-2-20240829","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0148607112450301","article-title":"Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition","volume":"37","author":"Burns","year":"2013","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R100-2-20240829","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/flgastro-2015-100560","article-title":"Reversal of intestinal failure-associated liver disease (IFALD): Emphasis on its multifactorial nature","volume":"7","author":"Hvas","year":"2016","journal-title":"Frontline Gastroenterol"},{"key":"R101-2-20240829","first-page":"1","article-title":"Fistuloclysis improves liver function and nutritional status in patients with high-output upper enteric fistula","volume":"2014","author":"Wu","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"R102-2-20240829","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s11605-010-1291-y","article-title":"Intestinal lengthening in adult patients with short bowel syndrome","volume":"14","author":"Yannam","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"R103-2-20240829","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/apt.15432","article-title":"Review article: Diagnosis and management of intestinal failure-associated liver disease in adults","volume":"50","author":"Bond","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R104-2-20240829","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ejcn.2015.147","article-title":"Chronic cholestasis in patients on parenteral nutrition: The influence of restoring bowel continuity after mesenteric infarction","volume":"70","author":"Adaba","year":"2015","journal-title":"Eur J Clin Nutr"},{"key":"R105-2-20240829","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3945\/ajcn.112.042606","article-title":"Increased intestinal absorption by segmental reversal of the small bowel in adult patients with short-bowel syndrome: A case-control study","volume":"97","author":"Layec","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"R106-2-20240829","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.idc.2016.07.001","article-title":"Prevention of vascular catheter-related bloodstream infections","volume":"30","author":"Rupp","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"R107-2-20240829","first-page":"38","article-title":"Practical approach to the management of catheter-related bloodstream infection","volume":"32","author":"Canton-Bulnes","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"R108-2-20240829","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1034\/j.1399-3046.2001.005002080.x","article-title":"Indications for pediatric intestinal transplantation: A position paper of the American Society of Transplantation","volume":"5","author":"Kaufman","year":"2001","journal-title":"Pediatr Transplant"},{"key":"R109-2-20240829","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/ajt.14715","article-title":"Visceral transplantation in patients with intestinal-failure associated liver disease: Evolving indications, graft selection, and outcomes","volume":"18","author":"Hawksworth","year":"2018","journal-title":"Am J Transplant"},{"key":"R110-2-20240829","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1572-0241.2000.02088.x","article-title":"Isolated intestinal transplantation for intestinal failure","volume":"95","author":"Sudan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R111-2-20240829","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.gtc.2018.01.011","article-title":"Adult intestinal transplantation","volume":"47","author":"Matsumoto","year":"2018","journal-title":"Gastroenterol Clin North Am"},{"key":"R112-2-20240829","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1097\/00007890-200112150-00025","article-title":"A new technique for combined liver\/small intestinal transplantation","volume":"72","author":"Sudan","year":"2001","journal-title":"Transplantation"},{"key":"R113-2-20240829","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2527\/jas.2011-4704","article-title":"Nonruminant nutrition symposium: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: Regulator or bystander.?","volume":"90","author":"Sigalet","year":"2012","journal-title":"J Anim Sci"},{"key":"R114-2-20240829","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ebiom.2019.07.017","article-title":"GLP-2 cures the gut-What about the liver?","volume":"46","author":"Pakarinen","year":"2019","journal-title":"EBioMedicine"},{"key":"R115-2-20240829","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0148607114551968","article-title":"Glucagon-like peptide 2 improves cholestasis in parenteral nutrition--associated liver disease","volume":"40","author":"Lim","year":"2016","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R116-2-20240829","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00383-019-04560-8","article-title":"Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome","volume":"35","author":"Yano","year":"2019","journal-title":"Pediatr Surg Int"},{"key":"R117-2-20240829","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ebiom.2019.07.016","article-title":"Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: Findings from a randomised phase 2 trial","volume":"46","author":"Naimi","year":"2019","journal-title":"EBioMedicine"},{"key":"R118-2-20240829","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.2006.02972.x","article-title":"Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure","volume":"24","author":"De Marco","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R119-2-20240829","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jpeds.2004.05.038","article-title":"Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis","volume":"145","author":"Chen","year":"2004","journal-title":"J Pediatr"},{"key":"R120-2-20240829","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0168-8278(05)80064-9","article-title":"Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease?","volume":"20","author":"Beau","year":"1994","journal-title":"J Hepatol"},{"key":"R121-2-20240829","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","article-title":"Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: A pilot study","volume":"42","author":"Kirpich","year":"2008","journal-title":"Alcohol"},{"key":"R122-2-20240829","doi-asserted-by":"crossref","first-page":"45176","DOI":"10.1038\/srep45176","article-title":"Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia","volume":"7","author":"Xue","year":"2017","journal-title":"Sci Rep"},{"key":"R123-2-20240829","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/gut.2005.080739","article-title":"Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress","volume":"55","author":"Zareie","year":"2006","journal-title":"Gut"},{"key":"R124-2-20240829","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ncp.10437","article-title":"Effects of probiotics on intestinal failure-associated liver disease in adult patients receiving prolonged parenteral support: A tertiary care center experience","volume":"35","author":"Alomari","year":"2020","journal-title":"Nutr Clin Pract"},{"key":"R125-2-20240829","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0148607185009004501","article-title":"Metronidazole prevention of serum liver enzyme abnormalities during total parenteral nutrition","volume":"9","author":"Lambert","year":"2016","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R126-2-20240829","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0140-6736(83)91442-3","article-title":"Metronidazole in prevention of cholestasis associated with total parenteral nutrition","volume":"321","author":"Capron","year":"1983","journal-title":"Lancet"},{"key":"R127-2-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","article-title":"Developments in bile salt based therapies: A critical overview","volume":"161","author":"Donkers","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"R128-2-20240829","doi-asserted-by":"crossref","first-page":"G108","DOI":"10.1152\/ajpgi.00356.2017","article-title":"FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection","volume":"317","author":"Cao","year":"2019","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"R129-2-20240829","first-page":"318","article-title":"FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease","volume":"3","author":"Olde Damink","year":"2017","journal-title":"J Clin Translational Res"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_551_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:31Z","timestamp":1786647271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_551_20"}},"subtitle":["A comprehensive review of the literature"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_551_20","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}